

Acronyms, Abbreviations, and Initials

Version 4.0

- AAAS** American Association for the Advancement of Science
- AABB** American Association of Blood Banks
- ADA** Abbreviated Antibiotic Drug Application (FDA) (used primarily for generics)
- AAMC** Association of American Medical Colleges
- AAPS** American Association of Pharmaceutical Scientists
- ABPI** Association of the British Pharmaceutical Industry
- ACCP** American College of Clinical Pharmacology
- ACDM** Association of Clinical Data Management (UK)
- ACE** Angiotensin-Converting Enzyme
- ACIL** A national trade association representing independent, commercial scientific, and engineering firms
- ACPU** Association of Clinical Pharmacology Units
- ACRA** Associate Commissioner for Regulatory Affairs (FDA)
- ACRP** Association of Clinical Research Professionals (formerly Associates in Clinical Pharmacology (ACP))
- ACRPI** Changed its name to ICR – Institute of Clinical Research (UK)
- ACT** Applied Clinical Trials magazine
- ACTG** AIDS Clinical Trials Group (NIAID)
- ACTU** AIDS Clinical Trials Unit (NIH)
- ADaM** Analysis Dataset Model (CDISC)
- ADAMHA** Alcohol, Drug Abuse, and Mental Health Administration (no longer exists)
- ADE** Adverse Drug Event; Adverse Drug Effect
- ADME** Absorption, Distribution, Metabolism, and Excretion (used to describe pharmacokinetic processes)
- ADR** Adverse Drug Reaction
- AE** Adverse Event
- AEGIS** ADROIT Electronically Generated Information Service, a subscription service that provides subscribing organizations with access to adverse drug reaction data from the Medicines Control Agency's ADROIT (Adverse Drug Reaction On-line Information Tracking) database
- AERS** Adverse Event Reporting System (FDA)
- AFCR** See *AFMR*.
- AFMR** American Federation for Medical Research, formerly the American Federation for Clinical Research (AFCR)
- AHA** American Heart Association
- AHCPR** Agency for Health Care Policy Research (NIH)
- AICRC** Association of Independent Clinical Research Contractors (UK)
- AIDS** Acquired Immune Deficiency Syndrome
- ALCOA** Attributable, Legible, Contemporaneous, Original, Accurate (dimensions of data integrity)
- AMA** American Medical Association
- AMC** antibody-mediated cytotoxicity
- AmFAR** American Foundation for AIDS Research
- AMG** Arzneimittelgesetz (German Drug Law)
- AMWA** American Medical Writers Association
- ANDA** Abbreviated New Drug Application (for a generic drug)
- ANOVA** analysis of variance (statistics)
- ANSI** American National Standards Institute
- AOAC** Association of Official Analytical Chemists
- APB** Association Pharmaceutique Belge (Belgium)
- APhA** American Pharmacists Association
- API** active pharmaceutical ingredient
- APPI** Academy of Pharmaceutical Physicians and Investigators
- ARCS** Association of Regulatory & Clinical Scientists (Australia)
- ARENA** Applied Research Ethics National Association
- ARO** academic research organization
- ASAP** administrative systems automation project (FDA)
- ASCII** American Standard Code for Information Interchange (computer files)
- ASCPT** American Society for Clinical Pharmacology and Therapeutics
- ASP** Application Service Provider delivering a computer application via the WWW
- ASQ** American Society for Quality, formerly American Society for Quality Control
- ATC** Anatomic-Therapeutic-Chemical Coding dictionary
- AUC** area under the curve (statistics)
- BARQA** British Association of Research Quality Assurance
- BCE** beneficial clinical event
- BDPA** Bureau of Drug Policy and Administration (China)
- BEUC** European Bureau of Consumer Unions

- BfArM** Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices, Germany)
- BGA** Bundesgesundheitsamt (Federal health office; former German public health agency)
- BGVV** Bundesinstitut für gesundheitlichen Verbraucherschutz und Veterinärmedizin (Federal Institute for Health Protection of Consumers and Veterinary Medicine, Germany)
- BIO** Biotechnology Industry Organization
- BIRA** British Institute of Regulatory Affairs
- BLA** Biologics License Application (FDA)
- BPI** Bundesverband der Pharmazeutischen Industrie EV (Germany)
- BrAPP** British Association of Pharmaceutical Physicians
- BRIDG** Biomedical Research Integrated Domain Group
- BSA** body surface area
- CA** Competent Authority (regulatory body charged with monitoring compliance with European Union member state national statutes and regulations)
- CAPRA** Canadian Association of Pharmaceutical Regulatory Affairs
- CAS** Chemical Abstracts Service
- CBER** Center for Biologics Evaluation and Research (FDA)
- CCI** Committee on Clinical Investigations. *See also Ethics Committee in the Glossary.*
- CCPPRB** Comité Consultative pour la Protection des Personnes dans les Recherches Biomédicales (France). *See also Ethics Committee in the Glossary.*
- CCRA** Certified Clinical Research Associate. Certification issued to monitors by ACRP.
- CCRC** Certified Clinical Research Coordinator. Certification issued to clinical coordinators by ACRP.
- CCRP** Certified Clinical Research Professional. SOCRA certification of coordinators, monitors, and other research professionals
- CDA** Clinical Document Architecture
- CDC** Centers for Disease Control and Prevention
- CDER** Center for Drug Evaluation and Research (FDA)
- CDISC** Clinical Data Interchange Standards Consortium
- CDM** Clinical Data Management
- CDRH** Center for Devices and Radiological Health (FDA)
- CEN** Comité Européen de Normalisation (European Committee for Standardization)
- CEU** Continuing Education Unit
- CF** Consent Form. *See also Informed Consent Form – ICF.*
- CFR** Code of Federal Regulations (usually cited by title and part; for example, Title 21, Part 211 is shown as 21 CFR 211)
- cGMP** current Good Manufacturing Practices
- CHI** Consolidated Health Initiative (eGov)
- CHR** Committee on Human Research. *See also Ethics Committee in the Glossary.*
- CIOMS** Council for International Organizations of Medical Sciences (postapproval international ADR reporting, UK)
- CIP** Certified IRB Professional
- CIS** Commonwealth of Independent States
- CLIA** Clinical Laboratory Improvements Amendments
- Cmax** Concentration maximum; used in pharmacokinetics and bioequivalence to indicate maximum plasma concentration for a drug
- CMC** Chemistry, Manufacturing, and Control
- CME** Continuing Medical Education
- CMMS** Centers for Medicare & Medicaid Services
- CNS** Central Nervous System
- CONSORT** Consolidated Standards of Reporting Trials
- COP** CDISC Operating Process/Procedure
- COSTART** Coding Symbols for a Thesaurus of Adverse Reaction Terms. *See also MedDRA.*
- CPHS** Committee for the Protection of Human Subjects
- CPMP** Committee for Proprietary Medicinal Products (EU)
- CPSC** Consumer Product Safety Commission (U.S.)
- CRA** Clinical Research Associate. *See also CCRA.*
- CRADA** Cooperative Research and Development Cooperative Research And Development Agreement (with US Government entities such as FDA or NIH)
- CRB** Case Record Book
- CRB** Central Review Board
- CRC** Clinical Research Coordinator. *See also CCRC, SC, SSC.*
- CRF** Case Report Form (sometimes case record form)
- CRO** Contract Research Organization. *See also IPRO.*
- CSDD** Center for the Study of Drug Development
- CSF** Collaborative Standards Forum (CDISC)
- CSF** Cerebrospinal Fluid
- CSF** Colony Stimulating Factor
- CSM** Committee on Safety of Medicines (UK)
- CSO** Consumer Safety Officer (FDA)
- CSR** Clinical Study Report
- CSU** Clinical Supply Unit
- CT** Clinical Trial
- CTA** Clinical Trial Agreement
- CTC** Clinical Trial Certificate (UK)
- CTD** Common Technical Document
- CTEP** Cancer Therapy Evaluation Program
- CTM** Clinical Trials Materials
- CTX** Clinical Trial Exemption (MCA)
- CV** Curriculum Vitae
- CVM** Center for Veterinary Medicine (FDA)
- DAWN** Drug Abuse Warning Network

- DD** Department of Drugs (Swedish regulatory agency)
- DEA** Drug Enforcement Administration (U.S.)
- DEN** Drug Experience Network
- DES** Data Encryption Standard
- DESI** Drug Efficacy Study Implementation notice (FDA, to evaluate drugs in use before 1962).
- DGPharMed** Deutsche Gesellschaft für Pharmazeutische Medizin (German Society of Pharmaceutical Medicine), formerly FÄPI
- DHEW** Department of Health, Education and Welfare (U.S., now split into DHHS and Department of Education)
- DHHS** Department of Health and Human Services (U.S.)
- DHTML** Dynamic HTML (IT)
- DIA** Drug Information Association
- DICOM** Digital Imaging and Communications in Medicine
- DLT** Dose-Limiting Toxicity
- DMB** Data Management Biomedical (France)
- DPC-PTR Act** Drug Price Competition and Patent Term Restoration Act of 1984 (also Waxman-Hatch or Hatch-Waxman bill)
- DSI** Division of Scientific Investigations (FDA)
- DSM** Diagnostic and Statistical Manual (of the American Psychiatric Association)
- DSMB** Data and Safety Monitoring Board
- DSNP** Development of Standardized Nomenclature Project (FDA)
- DTC** Direct-To-Consumer (drug advertising)
- DTD** Document Type Definition (XML)
- E3C** European CDISC Coordinating Committee
- EAB** Editorial Advisory Board (*Applied Clinical Trials*)
- EAB** Ethical Advisory Board. *See also Ethics Committee in the Glossary.*
- EC** Ethics Committee. *See also Ethics Committee in the Glossary.*
- EC** European Commission (in documents older than the mid-1980s, EC may mean European Community).
- ECG** electrocardiogram
- ECG** European CDISC Group
- ECJ** European Court of Justice
- ECOG** Eastern Cooperative Oncology Group (U.S.)
- ECPHIN** European Community Pharmaceutical Products Information Network
- eCRF** electronic Case Report Form
- eCTD** electronic Common Technical Document
- EDC** Electronic Data Capture/Collection
- EDI** electronic Data Interchange
- EEC** European Economic Community, now EU; some regulatory documents still have EEC document numbers.
- EFGCP** European Forum for Good Clinical Practice
- EFPIA** European Federation of Pharmaceutical Industries and Associations
- EFTA** European Free Trade Association
- eHR** electronic Health Record
- EIR** Establishment Inspection Report (FDA)
- ELA** Establishment License Application (FDA)
- EMA** European Agency for the Evaluation of Medicinal Products
- EMS** Electronic Mail Service
- EMWA** European Medical Writers Association
- EORTC** European Organization for the Research and Treatment of Cancer
- EP** European Parliament
- EPAR** European Public Assessment Report
- EPO** European Patent Office
- EPRG** European Pharmacovigilance Research Group
- ER** Essential Requirements (EMA)
- eRX** electronic Prescribing
- ESRA** European Society of Regulatory Affairs
- ESTRI** Electronic Standards for the Transfer of Regulatory Information (ICH)
- EU** European Union
- EUDRA** European Union Drug Regulatory Authorities
- EUDRACT** European Union clinical trials database
- EWG** expert working group
- FAQ** frequently asked questions
- Farindustria** The Association of Italian Pharmaceutical Manufacturers
- FD&C Act** Food, Drug, and Cosmetic Act (U.S.)
- FDA** Food and Drug Administration (U.S.)
- FDAMA** FDA Modernization Act
- FDLI** Food and Drug Law Institute
- FFPM** Fellow of the Faculty of Pharmaceutical Medicine (UK)
- FRCP** Fellow of the Royal College of Physicians, sometimes followed by a place name—for example, FRCP (Edin.)—that indicates a university medical school
- FTC** Federal Trade Commission (U.S.)
- FTP** File Transfer Protocol
- FWA** Federal-Wide Assurance
- GAO** General Accounting Office (U.S. government)
- GBP** Good Business Practice
- Gbps** gigabits, or billions of bits per second (data transmission)
- GCP** Good Clinical Practice
- GCRP** Good Clinical Research Practice
- GLP** Good Laboratory Practice
- GMP** Good Manufacturing Practice
- GP** General Practitioner; General Practice (UK)
- GPMS** Good Postmarketing Surveillance Practice (Japan)
- GRAS** Generally Regarded As Safe (foods)
- GXP** Good [Pharmaceutical] Practice

- HCFA** Health Care Financing Administration; now renamed The Centers for Medicare & Medicaid Services (CMMS).
- HEX** Human Experimentation Committee. *See also Ethics Committee in the Glossary.*
- HHS** Department of Health and Human Services (U.S., also called DHHS)
- HIMA** Health Industry Manufacturers Association
- HIMSS** Health Information and Management Systems Society
- HIPAA** Health Insurance Portability and Accountability Act
- HIT** Healthcare Information Technology
- HL7** Health Level 7 (a not-for-profit ANSI-accredited standards developing organization (SDO))
- HPB** Health Protection Branch, Laboratory Centre for Disease Control (Canada); has been superseded by Health Canada
- HPLC** High Performance Liquid Chromatography
- HSRC** Human Subjects Review Committee. *See also Ethics Committee in the Glossary.*
- HTML** Hypertext Markup Language
- HTTP** Hypertext Transfer Protocol
- IBC** India CDISC Coordinating Committee
- IAB** Industry Advisory Board (for CDISC)
- IB** Investigator's Brochure
- IC** Informed Consent
- ICD9** International Classification of Diseases, 9th revision. *See also MedDRA.*
- ICF** Informed Consent Form
- ICG** India CDISC Group
- ICH** International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
- ICR** Institute of Clinical Research (formerly ACRPI, Association for Clinical Research in the Pharmaceutical Industry, UK)
- ICSR** Individual Case Safety Report
- ICTH** International Committee on Thrombosis and Haemostases
- IEC** Independent Ethics Committee. *See also Ethics Committee in the Glossary.*
- IEEE** Institute of Electrical and Electronic Engineers, Inc.
- IFAPP** International Federation of Associations of Pharmaceutical Physicians
- IFPMA** International Federation of Pharmaceutical Manufacturers' Associations
- IG** Inspector General (HHS)
- IKS** Interkantonale Kontrollstelle für Heilmittel (Switzerland)
- IMP** Investigational Materials Plan
- IND** Investigational New Drug application (FDA). *See also TIND.*
- INN** International Nonproprietary Name
- IOM** Institute of Medicine (National Academy of Science, U.S.)
- IPRO** Independent Pharmaceutical Research Organization. *See also CRO.*
- IRB** Institutional Review Board; Independent Review Board. *See also Ethics Committee in the Glossary.*
- IRD** International Registration Document
- IS** International System of Units (may also be referred to as SI – Système Internationale)
- ISCB** International Society for Clinical Biostatistics
- ISDN** Integrated Services Digital Network
- ISO** International Organization for Standardization
- ISP** Internet Service Provider
- IT** Information Technology
- ITU-T** Telecommunication Standardization Sector of the International Telecommunications Union
- IVD** In Vitro Diagnostics
- IVRS** interactive voice response system
- J3C** Japan CDISC Coordinating Committee
- JCAHO** Joint Commission on Accreditation of Healthcare Organizations
- JCG** Japan CDISC Group
- JMA** Japan Medical Association
- JPMA** Japan Pharmaceutical Manufacturers Association
- Kbps** kilobits, or thousands of bits per second (data transmission)
- LAB** Laboratory Data Model (CDISC)
- LAN** local area network
- LIF** Swedish Pharmaceutical Industry Association
- LKP** Leiter der Klinischen Prüfung
- LOA** Letter Of Agreement
- LOINC** Logical Observations, Identifiers, Names, and Codes
- LREC** Local Research Ethics Committee (UK). *See also Ethics Committee in the Glossary.*
- MA** Marketing Authorization
- MAA** Marketing Authorisation Application (EU)
- MAH** Marketing Authorization Holder (EU)
- Mbps** megabits, millions of bits per second (data transmission)
- MCA** Medicines Control Agency (UK)
- MDR** Medical Device Reporting
- MedDRA** Medical Dictionary for Regulatory Activities (new global standard medical terminology designed to supersede other terminologies used in the medical product development process, including COSTART, ICD9, and others)
- MedID** Medicinal Product Identifier
- MEDLARS** Medical Literature Analysis and Retrieval System
- MEFA** Association of the Danish Pharmaceutical Industry
- MEP** Member of the European Parliament
- MHLW** Ministry of Health, Labor and Welfare (Japan)
- MIAME** Minimum Information About A Microarray

- Experiment (standard for microarray data)
- MOH** Ministry of Health (UK, Canada, others)
- MOPH** Ministry of Public Health
- MOU** Memorandum of Understanding (an MOU between FDA and a regulatory agency in another country allows mutual recognition of inspections)
- MPR** Medical Products Agency (Swedish Regulatory Agency)
- MR** Medical Representative (Japan)
- MRA** Medical Research Associate
- MREC** Multicentre Research Ethics Committee (UK). *See also Ethics Committee in the Glossary.*
- MRI** Magnetic Resonance Imaging
- MTD** Maximum Tolerated Dose
- MVP** Master Validation Plan
- NABR** National Association for Biomedical Research
- NAF** Notice of Adverse Findings (FDA post-audit letter)
- NAI** No Action Indicated (most favorable FDA post-inspection classification)
- NAS** New Active Substance (UK)
- NAS-NRC** National Academy of Sciences-National Research Council (U.S.)
- NBAC** National Bioethics Advisory Commission (U.S.)
- NCCAM** National Center for Complementary and Alternative Medicine, formerly Office of Alternative Medicine (NIH)
- NCCTG** North Central Cancer Treatment Group (U.S.)
- NCDM** Nordic Clinical Data Management (Association)
- NCE** New Chemical Entity
- NCHGR** National Center for Human Genome Research (NIH)
- NCHS** National Center for Health Statistics (in CDC)
- NCI** National Cancer Institute (NIH)
- NCPDP** National Council for Prescription Drug Programs
- NCPIE** National Council on Patient Information and Education (Washington DC)
- NCR** No Carbon [paper] Required
- NCRR** National Center for Research Resources (NIH)
- NCVIA** National Childhood Vaccine Injury Act (1986)
- NDA** New Drug Application (FDA)
- NDS** New Drug Submission (Canada's new drug application)
- NEFARMA** Dutch Association of the Innovative Pharmaceutical Industry
- NEI** National Eye Institute (NIH)
- NGO** NonGovernmental Organization
- NHI** National Health Insurance (Japan)
- NHIH** National Healthcare Information Network
- NHLBI** National Heart, Lung, and Blood Institute (NIH)
- NHS** National Health Service (UK)
- NIA** National Institute on Aging (NIH)
- NIAAA** National Institute on Alcohol Abuse and Alcoholism (NIH)
- NIAID** National Institute of Allergies and Infectious Diseases (NIH)
- NIAMS** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH)
- NICHD** National Institute of Child Health and Human Development (NIH)
- NIDA** National Institute on Drug Abuse (NIH)
- NIDCD** National Institute on Deafness and Other Communication Disorders (NIH)
- NIDDK** National Institute of Diabetes and Digestive and Kidney Diseases (NIH)
- NIDR** National Institute of Dental Research (NIH)
- NIHES** National Institute of Environmental Health Sciences (NIH)
- NIGMS** National Institute of General Medical Sciences (NIH)
- NIH** National Institutes of Health (DHHS)
- NIMH** National Institute of Mental Health (NIH)
- NINDS** National Institute of Neurological Disorders & Stroke (NIH)
- NINR** National Institute of Nursing Research (NIH)
- NIRB** Noninstitutional Review Board. *See also Ethics Committee, Independent IRB in the Glossary.*
- NLM** National Library of Medicine (NIH)
- NME** New Molecular Entity
- NOEL** No Observable Effect Level (dose of an experimental drug given preclinically, that does not produce an observable toxicity)
- NRB** noninstitutional review board, also known as an independent review board. *See also Ethics Committee in the Glossary, NIRB.*
- NSCLC** Non-Small Cell Lung Carcinoma
- NTP** National Toxicology Program
- OAI** Official Action Indicated (serious FDA post-inspection classification)
- OAM** *See NCCAM.*
- ODAC** Oncologic Drugs Advisory Committee (U.S.)
- ODE** Office of Drug Evaluation
- ODM** Operational Data Model [CDISC]
- OGD** Office of Generic Drugs (CDER, formerly DGB)
- OGE** Office of Government Ethics
- OHITA** Office of Health Information Technology Adoption
- OHRP** Office for Human Research Protections
- OIG** Office of the Inspector General
- OIS** Office of Interoperability and Standards
- OJC** Office Journal of the European Union-C Series (Information)
- OJEC** Official Journal of the European Communities

- OJL** Office Journal of the European Union-L Series (Legislation)
- OMB** Office of Management and Budget (U.S.)
- ONC** Office of the national Coordinator for Health Information Technology
- OPR** Office of Policy and Research
- OPRR** Office for Protection from Research Risks (predecessor to OHRP)
- OSHA** Occupational Safety Health Administration (U.S.)
- OTA** Office of Technology Assessment (U.S., abolished 1995)
- OTC** Over-The-Counter (refers to nonprescription drugs)
- PAB** Pharmaceutical Affairs Bureau (Japan)
- PAHO** Pan American Health Organization
- PCC** Poison Control Center
- PCP** *Pneumocystis carinii* pneumonia
- PD** pharmacodynamics
- PDA** Personal Digital Assistant (Palm Pilot(r), for example)
- PDF** Portable Document Format
- PDQ** Physicians' Data Query (NCI-sponsored cancer trial registry)
- PDR** Physicians' Desk Reference
- PDUFA** Prescription Drug User Fee Act (1992, U.S.)
- PEM** Prescription Event Monitoring
- PERI** Pharmaceutical Education & Research Institute (not-for-profit division of PhRMA)
- PFT** Pulmonary Function Tests
- PhPID** Pharmaceutical Product Identifier
- PhRMA** Pharmaceutical Research and Manufacturers of America (formerly PMA)
- PHS** Public Health Service (U.S.)
- PI** Principal Investigator
- PK** pharmacokinetics
- PKI** Public Key Infrastructure
- PLA** Product License Application (FDA)
- PMA** Pre-Market Approval application (FDA)
- PMS** Postmarketing Surveillance
- PPI** Patient Package Insert
- PPO** Preferred Provider Organization; Policy And Procedure Order
- PR** Partial Response; Pulse Rate
- PRIM&R** Public Responsibility in Medicine and Research (Boston, MA)
- PROG** Peer-Review Oversight Group (NIH)
- PSUR** Periodic Safety Update Report
- PTC** Points to Consider
- QA** Quality Assurance
- QAU** Quality Assurance Unit
- QC** Quality Control
- QL** Quality Of Life
- QOL** Quality Of Life (also QoL)
- R&D** Research and Development
- RADAR** Risk Assessment of Drugs-Analysis and Response
- RAPS** Regulatory Affairs Professionals Society
- RCRIM** Regulated Clinical Research and Information Management (HL7)
- RCT** Randomized Clinical Trial
- RDE** Remote Data Entry
- RDRC** Radioactive Drug Research Committee
- REB** Research Ethics Board (Canada)
- RHIO** Regional Health Information Organization
- RIM** Reference Information Model (HL7)
- RKI** Robert-Koch-Institut, Bundesinstitut für Infektionskrankheiten und nicht-übertragbare Krankheiten (Federal Institute for Infectious and Non-communicable Diseases, Germany)
- RL** Regulatory Letter (FDA – post-audit letter)
- SAE** Serious Adverse Event
- SAS** Statistical Analysis System (commonly used statistical analysis package)
- SATCM** State Administration of Traditional Chinese Medicine (China)
- SBA** Summary Basis of Approval
- SC** Study Coordinator. See also CRC, CCRC, SSC.
- SCDM** Society for Clinical Data Management (U.S.)
- SCT** Society for Clinical Trials
- SD** Standard Deviation (statistics)
- SDA** State Drug Administration (China)
- SDM** Submission Data Model (CDISC)
- SDO** Standards Development Organization
- SDS** Submission Data Standards (CDISC)
- SDV** Source Document (Data) Verification
- SE** Standard Error (statistics)
- SEA** Single European Act of 1987
- SEER** Surveillance, Epidemiology, and End Results program (National Cancer Institute)
- SGML** Standard Generalized Markup Language
- SIAC** Special Interest Area Community (DIA)
- SIG** Special Interest Group (HL7)
- SLA** Service Level Agreement
- SMART** Submission Management and Review Tracking (FDA)
- SME** Significant Medical Event
- SMO** Site Management Organization
- SmPC** Summary of Product Characteristics. See also SPC.
- SNDA** Supplemental New Drug Application
- SNIP** Syndicat National de l'Industrie Pharmaceutique (France)
- SNOMED** Systematized Nomenclature of Medicine (a dictionary)
- SoCRA** Society of Clinical Research Associates
- SOP** Standard Operating Procedure
- SPAC** State Pharmaceutical Administration of China
- SPC** Summary of Product Characteristics. See also SmPC.

Nuremberg Code—Directive for Human Experimentation

1. The voluntary consent of the human subject is absolutely essential. This means that the person involved should have legal capacity to give consent; should be so situated as to be able to exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, over-reaching, or other ulterior form of constraint or coercion; and should have sufficient knowledge and comprehension of the elements of the subject matter involved as to enable him to make an understanding and enlightened decision. This latter element requires that before the acceptance of an affirmative decision by the experimental subject there should be made known to him the nature, duration, and purpose of the experiment; the method and means by which it is to be conducted; all inconveniences and hazards reasonable to be expected; and the effects upon his health or person which may possibly come from his participation in the experiment. The duty and responsibility for ascertaining the quality of the consent rests upon each individual who initiates, directs or engages in the experiment. It is a personal duty and responsibility which may not be delegated to another with impunity.

2. The experiment should be such as to yield fruitful results for the good of society, unprocurable by other methods or means of study, and not random and unnecessary in nature.

3. The experiment should be so designed and based on the results of animal experimentation and a knowledge of the natural history of the disease or other problem under study that the anticipated results will

justify the performance of the experiment.

4. The experiment should be so conducted as to avoid all unnecessary physical and mental suffering and injury.

5. No experiment should be conducted where there is an a priori reason to believe that death or disabling injury will occur; except, perhaps, in those experiments where the experimental physicians also serve as subjects.

6. The degree of risk to be taken should never exceed that determined by the humanitarian importance of the problem to be solved by the experiment.

7. Proper preparations should be made and adequate facilities provided to protect the experimental subject against even remote possibilities of injury, disability, or death.

8. The experiment should be conducted only by scientifically qualified persons. The highest degree of skill and care should be required through all stages of the experiment of those who conduct or engage in the experiment.

9. During the course of the experiment the human subject should be at liberty to bring the experiment to an end if he has reached the physical or mental state where continuation of the experiment seems to him to be impossible.

10. During the course of the experiment the scientist in charge must be prepared to terminate the experiment at any stage, if he has probable cause to believe, in the exercise of the good faith, superior skill and careful judgment required of him that a continuation of the experiment is likely to result in injury, disability, or death to the experimental subject.

Reprinted from *Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10*, Vol. 2, pp. 181–182. Washington, D.C.: U.S. Government Printing Office, 1949.

SPM Society of Pharmaceutical Medicine (UK)

SQA Society of Quality Assurance

SQAP Systems Quality Assurance Plan

SSC Study Site Coordinator. See also *CRC, CCRC, SC*.

SSCT Swedish Society for Clinical Trials

SSFA Società di Scienze Farmacologiche Applicate (Italy)

SDTM Subject Data Tabulation Model

SPL Structured Product Labeling

STF Study Tagging File

STT Short Term Tests

SUA Serious Unexpected Adverse event

SUD Sudden Unexpected Death

SWOG Southwest Oncology Group (U.S.)

TC Technical Committee (HL7)

TCC Technical Coordinating Committee (CDISC)

TCP/IP Transmission Control Protocol/Internet Protocol

TermID Controlled Vocabulary Term Identifier

TESS Treatment Emergent Signs and Symptoms

TIND Treatment IND. See also *IND*.

TK toxicokinetics

Tmax the time after dosing when C_{max} occurs

TMO Trial Management Organization

URL Uniform Resource Locator (address of a Web site)

USAN United States Adopted Name

USC United States Code (book of laws)

USDA Department of Agriculture (U.S.)

USP United States Pharmacopeia

VA Veterans Administration (officially, United States Department of Veterans Affairs)

VAERS Vaccine Adverse Event Reporting System

VAI Voluntary Action Indicated (FDA postaudit inspection classification)

VGDS Voluntary Genomic Data Submission

VPN Virtual Private Network

WAN Wide Area Network

WHO World Health Organization

WHOART World Health Organization Adverse Reaction Terminology

WL Warning Letter (most serious FDA post-audit letter, demands immediate action within 15 days)

WR Written Request

WRAIR Walter Reed Army Institute of Research (DoD)

WTO World Trade Organization

www World Wide Web

XML eXtensible Markup Language